Article Sidebar

PDF
Date Published: 23/12/2021
Abstract Views: 352
Views PDF: 253
DOI: https://doi.org/10.51298/vmj.v507i2.1427
Issue
Vol. 507 No. 2 (2021)
Section
Các bài báo
How to Cite
Anh Tuấn, N. ., & Hồng Thăng, V. . (2021). RESULTS OF TREATMENT METASTATIC PROSTATE CANCER BY ANDROGEN DEPRIVATION THERAPY. Vietnam Medical Journal, 507(2). https://doi.org/10.51298/vmj.v507i2.1427

RESULTS OF TREATMENT METASTATIC PROSTATE CANCER BY ANDROGEN DEPRIVATION THERAPY

Nguyễn Anh Tuấn1,, Vũ Hồng Thăng1
1 Hanoi Medical University

Main Article Content

Abstract

Objective: To evaluate the efficiency of androgen deprivation therapy in metastatic prostate cancer. Patients and methods: Description study of 39 patients with metastatic prostate cancer who givenandrogen deprivation therapy between 2017 and June 2021. Results: Common clinical symptoms at the time of diagnosis: insomnia (66,7%), dysuria (69,2%), urinary frequency (56,4%), bone pain (59,0%). In which, 71,8% of patients choose surgical orchiectomy. After 3 months of treatment, the symptoms were significantly reduced: insomnia (17,9%), dysuria (20,5%), urinary frequency (5,1%), bone pain (28,2%). The mean progression-free survival (PFS) was 26,61±3,65months, in the surgical orchiectomy group was 22,62±3,45months, in the medical castration was 31,44±4,64 months, the difference was not statistically significant between two groups.  Conclusion: Androgen deprivation therapy is the cornerstone and effective treatment in metastatic prostate cancer.

Article Details

Keywords

prostate cancer, metastatic, Androgen deprivation therapy

References

1. Ferlay J., Colombet M., Soerjomataram I. và cộng sự. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 144(8), 1941–1953.
2. Tâm L.T.K. đánh giá kết quả điều trị nội tiết ung thư tuyến tiền liệt giai đoạn iv. 136.
3. Gandaglia G., Abdollah F., Schiffmann J. và cộng sự. (2014). Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. The Prostate, 74(2), 210–216.
4. Loblaw D.A., Mendelson D.S., Talcott J.A. và cộng sự. (2004). American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol, 22(14), 2927–2941.
5. Conn P.M. và Crowley W.F. (1991). Gonadotropin-releasing hormone and its analogues. N Engl J Med, 324(2), 93–103.
6. Waxman J., Man A., Hendry W.F. và cộng sự. (1985). Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J Clin Res Ed, 291(6506), 1387–1388.
7. Kaisary A.V., Tyrrell C.J., Peeling W.B. và cộng sự. (1991). Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol, 67(5), 502–508.